Skip to main content

Table 1 Antitumor efficacy of the experimental formulation of LCS 1269 for B16 melanoma

From: A new indolocarbazole derivative in melanoma and carcinoma lung in vivo treatment

Route of administration

Dose (mg/kg)/ interval (h) x number of administrations

TGI (%)

Days post-treatment

ILS (%)

Death of animals (%)

1

4

8

12

16

i.v.

60/24Ñ…5

90*

92*

67*

58*

66*

–

17

100Ñ…1

98*

94*

81*

73*

82*

24*

0

120Ñ…1

95*

94*

85*

79*

77*

4

0

i.p.

60/24Ñ…5

95*

98*

83*

76*

73*

26*

0

per os

120/96Ñ…2

66*

67*

43

47

64*

9

0

s.c.

60/24Ñ…5

83*

78*

45

41

60*

25*

0

120/96Ñ…2

78*

75*

42

32

63*

–

50

  1. Note: * р < 0.05 compared with control
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us